Edesa Historical Financial Ratios
| EDSA Stock | USD 1.78 0.12 6.32% |
Edesa Biotech is recently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 115 or Days Sales Outstanding of 92.27 will help investors to properly organize and evaluate Edesa Biotech financial condition quickly.
Edesa |
About Edesa Financial Ratios Analysis
Edesa BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Edesa Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Edesa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Edesa Biotech history.
Edesa Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Edesa Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Edesa Biotech sales, a figure that is much harder to manipulate than other Edesa Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Edesa Biotech dividend as a percentage of Edesa Biotech stock price. Edesa Biotech dividend yield is a measure of Edesa Biotech stock productivity, which can be interpreted as interest rate earned on an Edesa Biotech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Edesa Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's PTB Ratio is expected to grow to 115.07, whereas Free Cash Flow Yield is forecasted to decline to (0.01).
| 2023 | 2024 (projected) | Days Sales Outstanding | 63.81 | 92.27 | PTB Ratio | 109.59 | 115.07 |
Edesa Biotech fundamentals Correlations
Click cells to compare fundamentals
Edesa Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edesa Biotech fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 131.79 | 69.52 | 211.25 | 2.3K | 2.6K | 2.7K | |
| Ptb Ratio | 10.47 | 6.82 | 1.44 | 1.79 | 109.59 | 115.07 | |
| Days Sales Outstanding | 71.06 | 192.86 | 97.07 | 55.49 | 63.81 | 92.27 | |
| Book Value Per Share | 5.39 | 7.57 | 4.48 | 2.47 | 42.65 | 44.66 | |
| Free Cash Flow Yield | (0.0723) | (0.15) | (0.91) | (0.53) | (0.005386) | (0.005656) | |
| Operating Cash Flow Per Share | (4.06) | (7.92) | (5.86) | (2.32) | (23.63) | (24.81) | |
| Stock Based Compensation To Revenue | 0.73 | 0.11 | 1.82 | 2.57 | 2.96 | 2.02 | |
| Capex To Depreciation | 0.6 | 0.0517 | 0.0479 | 1.6E-5 | 1.76 | 1.83 | |
| Pb Ratio | 10.47 | 6.82 | 1.44 | 1.79 | 109.59 | 115.07 | |
| Ev To Sales | 111.84 | 57.28 | 189.81 | 2.2K | 2.6K | 2.7K | |
| Free Cash Flow Per Share | (4.08) | (7.93) | (5.86) | (2.32) | (25.18) | (26.44) | |
| Roic | (0.94) | (1.81) | (1.95) | (1.31) | (0.75) | (0.78) | |
| Inventory Turnover | (0.47) | (0.2) | (0.0941) | 9.29 | 10.69 | 11.22 | |
| Net Income Per Share | (5.18) | (7.74) | (8.37) | (2.93) | (46.75) | (49.08) | |
| Days Of Inventory On Hand | (782.36) | (1.8K) | (3.9K) | 39.27 | 45.16 | 47.42 | |
| Payables Turnover | 0.24 | 0.0121 | 0.0861 | 0.0557 | 0.11 | 0.12 | |
| Sales General And Administrative To Revenue | 13.02 | 4.98 | 10.29 | 7.72 | 6.94 | 6.19 | |
| Research And Ddevelopement To Revenue | 9.85 | 2.67 | 10.13 | 6.61 | 5.95 | 3.74 | |
| Capex To Revenue | 1.81 | 0.0197 | 0.1 | 0.75 | 0.67 | 0.4 | |
| Cash Per Share | 5.87 | 4.54 | 3.38 | 1.88 | 76.91 | 48.93 | |
| Pocfratio | (13.93) | (6.52) | (1.1) | (1.9) | (197.8) | (187.91) | |
| Capex To Operating Cash Flow | (0.006887) | (4.5E-4) | (4.61E-4) | 0.0 | (0.0654) | (0.0687) | |
| Pfcf Ratio | (13.83) | (6.52) | (1.1) | (1.9) | (185.66) | (176.37) | |
| Days Payables Outstanding | 30.3K | 4.2K | 6.6K | 3.5K | 3.1K | 4.7K | |
| Income Quality | 1.75 | 0.78 | 1.02 | 0.7 | 0.79 | 0.69 | |
| Roe | (0.96) | (1.02) | (1.87) | (1.19) | (1.1) | (1.15) | |
| Ev To Operating Cash Flow | (12.52) | (5.95) | (0.52) | (1.11) | (194.65) | (184.92) | |
| Pe Ratio | (10.91) | (6.68) | (0.77) | (1.51) | (100.0) | (95.0) | |
| Return On Tangible Assets | (0.77) | (1.09) | (1.89) | (1.25) | (0.58) | (0.61) | |
| Ev To Free Cash Flow | (12.43) | (5.95) | (0.52) | (1.11) | (182.7) | (173.57) | |
| Earnings Yield | (0.0953) | (0.0916) | (0.15) | (1.3) | (0.01) | (0.0105) | |
| Net Debt To E B I T D A | 1.78 | 1.11 | 0.59 | 0.41 | 0.64 | 1.63 | |
| Current Ratio | 5.3 | 8.29 | 4.25 | 3.53 | 9.9 | 11.15 | |
| Tangible Book Value Per Share | 3.37 | 6.19 | 3.39 | 1.7 | 42.65 | 43.64 | |
| Receivables Turnover | 5.14 | 1.89 | 3.76 | 6.58 | 5.92 | 5.62 | |
| Graham Number | 25.06 | 36.3 | 29.05 | 12.75 | 211.81 | 209.04 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.